TEVOGEN BIO ONCOLOGY REPORTS TOP-LINE REVENUE FORECAST OF $1 BILLION IN LAUNCH YEAR AND CUMULATIVE 5-YEAR ESTIMATE BETWEEN $10 BILLION AND $14 BILLION; FORECASTS FOR NON-ONCOLOGY THERAPEUTIC AREAS TO FOLLOW

Reuters · 10/17 13:32

Please log in to view news